Diquafosol is a purinergic receptor agonist primarily prescribed for the treatment of dry eye disease. This therapeutic agent works by stimulating P2Y2 receptors on the ocular surface, which promotes the… Read more

![Chemical structure of 1-[3-(Dimethylamino)propyl]-3-ethylurea](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F32897-26-0-1-3-Dimethylaminopropyl-3-ethylurea.png&w=3840&q=75)















Diquafosol is a purinergic receptor agonist primarily prescribed for the treatment of dry eye disease. This therapeutic agent works by stimulating P2Y2 receptors on the ocular surface, which promotes the secretion of mucin and tears to improve corneal health. This category offers a comprehensive selection of reference standards for the Diquafosol active pharmaceutical ingredient (API), alongside its pharmacopeial and non-pharmacopeial impurities. Laboratories utilize these high-quality compounds, including identified metabolites and stable isotope-labelled standards, to support rigorous analytical testing and method validation. By incorporating these specific materials, researchers can perform accurate impurity profiling and quantitative analysis throughout the drug development lifecycle, ensuring compliance with quality control standards for ocular formulations.